US0070021086
© BusinessWire
28.11.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025.
One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025.
“We were pleased to announce positive preliminary data last month...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025.
Five individuals were hired by Adicet in October 2025. In the aggregate, Adicet granted new hires non-qual...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
28.10.2025
ACET
LISTED
NASDAQ
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference bein...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
16.10.2025
ACET
LISTED
NASDAQ
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA.
“Dosing the first patient in our clinical...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ACET
LISTED
NASDAQ
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
News Preview
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investor...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ACET
LISTED
NASDAQ
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase 1 study evaluating ADI-001 as a potential treatment for...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on September 30, 2025.
One individual was hired by Adicet in September 2025 and granted new hire non-qualified stock options...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ACET
LISTED
NASDAQ
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025.
Two individuals were hired by Adicet in August 2025. In the aggregate, Adicet granted new hires non-qualifi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
ACET
LISTED
NASDAQ
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (SSc) patient has been dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases....
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
ACET
LISTED
NASDAQ
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
06.05.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025.
“We are approaching an exciting inflection point for our pipeline, wi...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025.
Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualifie...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
ACET
LISTED
NASDAQ
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
ACET
LISTED
NASDAQ
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
ACET
LISTED
NASDAQ
Adicet Bio Appoints Michael Grissinger to the Board of Directors
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy,...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025.
Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
ACET
LISTED
NASDAQ
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being hel...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024.
“In 2025 we plan to continue advancing our gamma delta 1...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
ACET
LISTED
NASDAQ
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking plac...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ACET
LISTED
NASDAQ
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
ACET
LISTED
NASDAQ
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory system...
Themefolio
Profiler
Peergroup
© BusinessWire
01.02.2025
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025.
Two individuals were hired by Adicet in January 2025. In the aggregate, Adicet granted new hires non-quali...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
ACET
LISTED
NASDAQ
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being hel...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ACET
LISTED
NASDAQ
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025.
“2024 was a momentous year for Adicet as we amplified our efforts in autoimmune diseases and...
Themefolio
Profiler
Peergroup
© BusinessWire
31.12.2024
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on December 31, 2024.
One individual was hired by Adicet in December 2024 and granted new hire non-qualified stock options to...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
ACET
LISTED
NASDAQ
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC.
“Dosing the first patient...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
ACET
LISTED
NASDAQ
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy...
Themefolio
Profiler
Peergroup
© BusinessWire
29.11.2024
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024.
One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ACET
LISTED
NASDAQ
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
“S...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ACET
LISTED
NASDAQ
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.
“Dosing the first lupus nephritis patient...
Themefolio
Profiler
Peergroup
© BusinessWire
16.11.2024
ACET
LISTED
NASDAQ
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
ACET
LISTED
NASDAQ
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024.
“Our commitment to delivering best-in-class gamma delta 1 T cell...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
ACET
LISTED
NASDAQ
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Wash...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
ACET
LISTED
NASDAQ
Adicet Bio to Participate in Upcoming Investor Conferences
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November.
Details of the events are as follows:
Truist Securities BioPhar...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024.
Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qual...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ACET
LISTED
NASDAQ
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amendment to the Company’s Investigational New Drug (IND) application to evaluate ADI-001 in...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024.
Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-q...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ACET
LISTED
NASDAQ
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer con...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ACET
LISTED
NASDAQ
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.
“The favorable safety profile, cellular kinetics and B ce...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
ACET
LISTED
NASDAQ
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2024
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024.
Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-quali...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
ACET
LISTED
NASDAQ
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
ACET
LISTED
NASDAQ
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors.
“We are pleased to welcome Dr. Klickstein to our Board of Directors,” said Chen...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
ACET
LISTED
NASDAQ
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024.
“We believe ADI-001 has best-in-class potential for autoimmune disea...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
